201 related articles for article (PubMed ID: 33184494)
21. Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-κB signaling.
Buchan SL; Al-Shamkhani A
PLoS One; 2012; 7(9):e45244. PubMed ID: 23028875
[TBL] [Abstract][Full Text] [Related]
22. Cellular and Molecular Mechanisms of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
DeCoster RC; Clemens MW; Di Napoli A; Lynch EB; Bonaroti AR; Rinker BD; Butterfield TA; Vasconez HC
Plast Reconstr Surg; 2021 Jan; 147(1):30e-41e. PubMed ID: 33370049
[TBL] [Abstract][Full Text] [Related]
23. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
[TBL] [Abstract][Full Text] [Related]
24. Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma.
Mura G; Karaca Atabay E; Menotti M; Martinengo C; Ambrogio C; Giacomello G; Arigoni M; Olivero M; Calogero RA; Chiarle R; Voena C
Front Oncol; 2022; 12():1085672. PubMed ID: 36698412
[TBL] [Abstract][Full Text] [Related]
25. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.
Hamedani FS; Cinar M; Mo Z; Cervania MA; Amin HM; Alkan S
Leuk Res; 2014 Apr; 38(4):503-8. PubMed ID: 24486291
[TBL] [Abstract][Full Text] [Related]
26. The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.
Muro I; Fang G; Gardella KA; Mahajan IM; Wright CW
Cell Cycle; 2014; 13(12):1918-27. PubMed ID: 24739416
[TBL] [Abstract][Full Text] [Related]
27. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
[TBL] [Abstract][Full Text] [Related]
28. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
[TBL] [Abstract][Full Text] [Related]
29. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
30. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
[TBL] [Abstract][Full Text] [Related]
31. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells.
Wright CW; Rumble JM; Duckett CS
J Biol Chem; 2007 Apr; 282(14):10252-62. PubMed ID: 17261581
[TBL] [Abstract][Full Text] [Related]
32. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
Watanabe M; Sasaki M; Itoh K; Higashihara M; Umezawa K; Kadin ME; Abraham LJ; Watanabe T; Horie R
Cancer Res; 2005 Sep; 65(17):7628-34. PubMed ID: 16140928
[TBL] [Abstract][Full Text] [Related]
33. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
34. The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation.
Unger C; Kiss I; Vasas A; Lajter I; Kramer N; Atanasov AG; Nguyen CH; Chatuphonprasert W; Brenner S; Krieger S; McKinnon R; Peschel A; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
Phytomedicine; 2015 Aug; 22(9):862-74. PubMed ID: 26220634
[TBL] [Abstract][Full Text] [Related]
35. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
[TBL] [Abstract][Full Text] [Related]
36. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.
Babin L; Darchen A; Robert E; Aid Z; Borry R; Soudais C; Piganeau M; De Cian A; Giovannangeli C; Bawa O; Rigaud C; Scoazec JY; Couronné L; Veleanu L; Cieslak A; Asnafi V; Sibon D; Lamant L; Meggetto F; Mercher T; Brunet E
Mol Cancer; 2022 Mar; 21(1):65. PubMed ID: 35246138
[TBL] [Abstract][Full Text] [Related]
37. ALK-transformed mature T lymphocytes restore early thymus progenitor features.
Congras A; Hoareau-Aveilla C; Caillet N; Tosolini M; Villarese P; Cieslak A; Rodriguez L; Asnafi V; Macintyre E; Egger G; Brousset P; Lamant L; Meggetto F
J Clin Invest; 2020 Dec; 130(12):6395-6408. PubMed ID: 33141118
[TBL] [Abstract][Full Text] [Related]
38. A novel model of controlling PD-L1 expression in ALK
Zhang JP; Song Z; Wang HB; Lang L; Yang YZ; Xiao W; Webster DE; Wei W; Barta SK; Kadin ME; Staudt LM; Nakagawa M; Yang Y
Blood; 2019 Jul; 134(2):171-185. PubMed ID: 31151983
[TBL] [Abstract][Full Text] [Related]
39. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
40. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
Rajan SS; Amin AD; Li L; Rolland DC; Li H; Kwon D; Kweh MF; Arumov A; Roberts ER; Yan A; Basrur V; Elenitoba-Johnson KSJ; Chen XS; Puvvada SD; Lussier YA; Bilbao D; Lim MS; Schatz JH
Oncogene; 2020 Mar; 39(10):2103-2117. PubMed ID: 31804622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
